Tamsulosin Hydrochloride
Product Images NDC 50436-0598

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 50436-0598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504360598)

Tamsulosin Hydrochloride 0.4 mg capsule label from Unit Dose Services. The label shows a single-dose capsule packaging containing 30 capsules. It includes active ingredient information, manufacturer details (Barducco Pharma USA, Inc.), and lot and expiration placeholders. The label also has warnings about proper storage and keeping out of reach of children.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride (ng/mL) over time (hours) following a single 0.4 mg capsule dose under fasted and fed conditions. The graph compares the concentration-time profiles with a dashed line for fasted and a solid line for fed states, covering 0 to 36 hours.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph showing mean change from baseline in total AUA symptom score over 13 weeks plus LOCF. The x-axis represents duration of treatment in weeks, and the y-axis shows mean symptom score change. The graph compares three treatments: 0.8 mg, 0.4 mg, and placebo, with respective lines marked by circles, triangles, and squares.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph showing the mean change from baseline in total AUA symptom score over a 13-week treatment period from Study 2. The x-axis represents treatment duration in weeks, and the y-axis shows mean change. Data are presented for three treatment groups: 0.8 mg, 0.4 mg, and placebo. Symbols represent the groups: circles for 0.8 mg, triangles for 0.4 mg, and squares for placebo.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in mL/sec on the y-axis and duration of treatment in weeks on the x-axis. It compares three treatment groups: 0.8 mg, 0.4 mg, and placebo, with the 0.8 mg and 0.4 mg groups showing higher mean increases over time compared to placebo.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' depicting mean change in urine flow rate over treatment duration in weeks. The graph compares three treatments: 0.8 mg, 0.4 mg, and placebo, with mean change on the y-axis and weeks on the x-axis, showing trends for each treatment group.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride showing the molecular arrangement of atoms including sulfur, nitrogen, oxygen, and chlorine elements associated with the hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.